Heterogeneous response of cardiac sympathetic function to cardiac resynchronization therapy in heart failure documented by 11[C]-hydroxy-ephedrine and PET/CT

Selene Capitanio, Cristina Nanni, Cecilia Marini, Rachele Bonfiglioli, Cristian Martignani, Bassam Dib, Chiara Fuccio, Giuseppe Boriani, Lorena Picori, Stefano Boschi, Silvia Morbelli, Stefano Fanti, Gianmario Sambuceti

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Introduction: Cardiac resynchronization therapy (CRT) is an accepted treatment in patients with end-stage heart failure. PET permits the absolute quantification of global and regional homogeneity in cardiac sympathetic innervation. We evaluated the variation of cardiac adrenergic activity in patients with idiopathic heart failure (IHF) disease (NYHA III-IV) after CRT using 11C-hydroxyephedrine (HED) PET/CT. Methods: Ten IHF patients (mean age. = 68; range. = 55-81; average left ventricular ejection fraction 26 ± 4%) implanted with a resynchronization device underwent three HED PET/CT studies: PET 1 one week after inactive device implantation; PET 2, one week after PET 1 under stimulated rhythm; PET 3, at 3 months under active CRT. A dedicated software (PMOD 3.4 version) was used to estimate global and regional cardiac uptake of HED through 17 segment polar maps. Results: At baseline, HED uptake was heterogeneously distributed throughout the left ventricle with a variation coefficient of 18 ± 5%. This variable markedly decreased after three months CRT (12 ± 5%, p.

Original languageEnglish
Pages (from-to)858-863
Number of pages6
JournalNuclear Medicine and Biology
Volume42
Issue number11
DOIs
Publication statusPublished - Nov 1 2015

Fingerprint

Ephedrine
Cardiac Resynchronization Therapy
Heart Failure
Equipment and Supplies
Stroke Volume
Adrenergic Agents
Heart Ventricles
Heart Diseases
Software
Therapeutics

Keywords

  • C-hydroxyephedrine
  • Cardiac resynchronization therapy
  • Heart failure
  • PET/CT
  • Sympathetic innervation

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Medicine
  • Radiology Nuclear Medicine and imaging

Cite this

Heterogeneous response of cardiac sympathetic function to cardiac resynchronization therapy in heart failure documented by 11[C]-hydroxy-ephedrine and PET/CT. / Capitanio, Selene; Nanni, Cristina; Marini, Cecilia; Bonfiglioli, Rachele; Martignani, Cristian; Dib, Bassam; Fuccio, Chiara; Boriani, Giuseppe; Picori, Lorena; Boschi, Stefano; Morbelli, Silvia; Fanti, Stefano; Sambuceti, Gianmario.

In: Nuclear Medicine and Biology, Vol. 42, No. 11, 01.11.2015, p. 858-863.

Research output: Contribution to journalArticle

Capitanio, Selene ; Nanni, Cristina ; Marini, Cecilia ; Bonfiglioli, Rachele ; Martignani, Cristian ; Dib, Bassam ; Fuccio, Chiara ; Boriani, Giuseppe ; Picori, Lorena ; Boschi, Stefano ; Morbelli, Silvia ; Fanti, Stefano ; Sambuceti, Gianmario. / Heterogeneous response of cardiac sympathetic function to cardiac resynchronization therapy in heart failure documented by 11[C]-hydroxy-ephedrine and PET/CT. In: Nuclear Medicine and Biology. 2015 ; Vol. 42, No. 11. pp. 858-863.
@article{40809e6a7aa04f8fb491ef393c101a1d,
title = "Heterogeneous response of cardiac sympathetic function to cardiac resynchronization therapy in heart failure documented by 11[C]-hydroxy-ephedrine and PET/CT",
abstract = "Introduction: Cardiac resynchronization therapy (CRT) is an accepted treatment in patients with end-stage heart failure. PET permits the absolute quantification of global and regional homogeneity in cardiac sympathetic innervation. We evaluated the variation of cardiac adrenergic activity in patients with idiopathic heart failure (IHF) disease (NYHA III-IV) after CRT using 11C-hydroxyephedrine (HED) PET/CT. Methods: Ten IHF patients (mean age. = 68; range. = 55-81; average left ventricular ejection fraction 26 ± 4{\%}) implanted with a resynchronization device underwent three HED PET/CT studies: PET 1 one week after inactive device implantation; PET 2, one week after PET 1 under stimulated rhythm; PET 3, at 3 months under active CRT. A dedicated software (PMOD 3.4 version) was used to estimate global and regional cardiac uptake of HED through 17 segment polar maps. Results: At baseline, HED uptake was heterogeneously distributed throughout the left ventricle with a variation coefficient of 18 ± 5{\%}. This variable markedly decreased after three months CRT (12 ± 5{\%}, p.",
keywords = "C-hydroxyephedrine, Cardiac resynchronization therapy, Heart failure, PET/CT, Sympathetic innervation",
author = "Selene Capitanio and Cristina Nanni and Cecilia Marini and Rachele Bonfiglioli and Cristian Martignani and Bassam Dib and Chiara Fuccio and Giuseppe Boriani and Lorena Picori and Stefano Boschi and Silvia Morbelli and Stefano Fanti and Gianmario Sambuceti",
year = "2015",
month = "11",
day = "1",
doi = "10.1016/j.nucmedbio.2015.07.002",
language = "English",
volume = "42",
pages = "858--863",
journal = "Nuclear Medicine and Biology",
issn = "0969-8051",
publisher = "Elsevier Inc.",
number = "11",

}

TY - JOUR

T1 - Heterogeneous response of cardiac sympathetic function to cardiac resynchronization therapy in heart failure documented by 11[C]-hydroxy-ephedrine and PET/CT

AU - Capitanio, Selene

AU - Nanni, Cristina

AU - Marini, Cecilia

AU - Bonfiglioli, Rachele

AU - Martignani, Cristian

AU - Dib, Bassam

AU - Fuccio, Chiara

AU - Boriani, Giuseppe

AU - Picori, Lorena

AU - Boschi, Stefano

AU - Morbelli, Silvia

AU - Fanti, Stefano

AU - Sambuceti, Gianmario

PY - 2015/11/1

Y1 - 2015/11/1

N2 - Introduction: Cardiac resynchronization therapy (CRT) is an accepted treatment in patients with end-stage heart failure. PET permits the absolute quantification of global and regional homogeneity in cardiac sympathetic innervation. We evaluated the variation of cardiac adrenergic activity in patients with idiopathic heart failure (IHF) disease (NYHA III-IV) after CRT using 11C-hydroxyephedrine (HED) PET/CT. Methods: Ten IHF patients (mean age. = 68; range. = 55-81; average left ventricular ejection fraction 26 ± 4%) implanted with a resynchronization device underwent three HED PET/CT studies: PET 1 one week after inactive device implantation; PET 2, one week after PET 1 under stimulated rhythm; PET 3, at 3 months under active CRT. A dedicated software (PMOD 3.4 version) was used to estimate global and regional cardiac uptake of HED through 17 segment polar maps. Results: At baseline, HED uptake was heterogeneously distributed throughout the left ventricle with a variation coefficient of 18 ± 5%. This variable markedly decreased after three months CRT (12 ± 5%, p.

AB - Introduction: Cardiac resynchronization therapy (CRT) is an accepted treatment in patients with end-stage heart failure. PET permits the absolute quantification of global and regional homogeneity in cardiac sympathetic innervation. We evaluated the variation of cardiac adrenergic activity in patients with idiopathic heart failure (IHF) disease (NYHA III-IV) after CRT using 11C-hydroxyephedrine (HED) PET/CT. Methods: Ten IHF patients (mean age. = 68; range. = 55-81; average left ventricular ejection fraction 26 ± 4%) implanted with a resynchronization device underwent three HED PET/CT studies: PET 1 one week after inactive device implantation; PET 2, one week after PET 1 under stimulated rhythm; PET 3, at 3 months under active CRT. A dedicated software (PMOD 3.4 version) was used to estimate global and regional cardiac uptake of HED through 17 segment polar maps. Results: At baseline, HED uptake was heterogeneously distributed throughout the left ventricle with a variation coefficient of 18 ± 5%. This variable markedly decreased after three months CRT (12 ± 5%, p.

KW - C-hydroxyephedrine

KW - Cardiac resynchronization therapy

KW - Heart failure

KW - PET/CT

KW - Sympathetic innervation

UR - http://www.scopus.com/inward/record.url?scp=84943363642&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84943363642&partnerID=8YFLogxK

U2 - 10.1016/j.nucmedbio.2015.07.002

DO - 10.1016/j.nucmedbio.2015.07.002

M3 - Article

C2 - 26239084

AN - SCOPUS:84943363642

VL - 42

SP - 858

EP - 863

JO - Nuclear Medicine and Biology

JF - Nuclear Medicine and Biology

SN - 0969-8051

IS - 11

ER -